C-terminal apolipoprotein E-derived peptide, Ep1.B, displays anti-atherogenic activity

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 116-124

  Bocksch, Leila ^a,b   Rider, Beverly J ^b   Stephens, Tracey ^b   Dai, Erbin ^a   Liu, Liying ^a   Diao, Hong ^a   Viswanathan, Kasinath ^a,b   Munuswamy Ramanujam, Ganesh ^a,b,d   Singh, Bhagirath ^b,e   Lucas, Alexandra ^a,b,c,d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b Department of Microbiology and Immunology ^*  (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

Apolipoprotein E (ApoE); Atherosclerosis; Lipids; Major histocompatibility complex II (MHC II); Neointima

Indexed keywords

ALANINE; AMINO ACID; APOLIPOPROTEIN E; LIPID BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROGENIC ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MECHANISM; IMMUNOREGULATION; LIPID METABOLISM; LIPID TRANSPORT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; TISSUE INJURY; VASCULAR SURGERY;

ANGIOPLASTY; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; FEMALE; FEMORAL ARTERY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYPERPLASIA; ILIAC ARTERY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES; TUNICA INTIMA;

EID: 34648843007     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.014     Document Type: Article

References (33)

1. Westerlund J.A., and Weisgraber K.H. Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem 268 (1993) 15745-15750
2. Ishibashi S., Herz J., Maeda N., Goldstein J.L., and Brown M.S. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 91 (1994) 4431-4435
3. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., and Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252 (1991) 1817-1822
4. Bocksch L., Stephens T., Lucas A., and Singh B. Apolipoprotein E: possible therapeutic target for atherosclerosis. Curr Drug Targets: Card Haematol Dis 1 (2001) 93-106
5. Plump A.S., Smith J.D., Hayek T., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
6. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
7. Nakashima Y., Plump A.S., Raines E.W., Breslow J., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
8. Hoen P.A.C., Christian A.C., der Lans V., et al. Aorta of apoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 93 (2003) 262-269
9. Zhu B., Kuhel D.G., Witte D.P., and Hui D.Y. Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol 157 (2000) 1839-1848
10. Bellosta S., Mahley R.W., Sanan D.A., et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96 (1995) 2170-2179
11. Wientgen H., Thorngate F.E., Omerhodzic S., et al. Subphysiologic apolipoprotein E (apoE) plasma levels inhibit neointimal formation after arterial injury in apoE-deficient mice. Atheroscler Thromb Vasc Biol 2 (2004) 1-6
12. Yamada N., Inoue I., Kawamura M., et al. Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 89 (1992) 706-711
13. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240 (1988) 622-630
14. Dyer C.A., Smith R.S., and Curtiss L.K. Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. J Biol Chem 266 (1991) 15009-15015
15. Cardin A.D., Bowlin T.L., and Krstenansky J.L. Inhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E. Biochem Biophys Res Commun 154 (1988) 741-745
16. Swertfeger D.K., and Hui D.Y. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 276 (2001) 25043-25048
17. Riddell D.R., Graham A., and Owen J.S. Apolipoprotein E inhibits platelet aggregation through the l-arginine: nitric oxide pathway. J Biol Chem 272 (1997) 89-95
18. Klezovitch O., Formato M., Cherchi G.M., Weisgraber K.H., and Scanu A.M. Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan. J Biol Chem 275 (2000) 18913-18918
19. Forstner M., Peters-Libeu C., Contreras-Forrest E., et al. Carboxyl-terminal domain of human apolipoprotein E: expression, purification, and crystallization. Protein Expr Purif 17 (1999) 267-272
20. Robertson A.-K.L., Rudling M., Zhou X., et al. Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J Clin Invest 112 (2003) 1342-1350
21. Murphy N., Bruckdorfer R., Grimsditch D.C., et al. Temporal relationships between circulating levels of CC and CXC chemokines and developing atherosclerosis in apolipoprotein E*3 Leiden mice. Arterioscler Thromb Vasc Biol 23 (2003) 1615-1620
22. Lutgens E., Gorelik L., Daemen M.J., et al. Requirements for CD154 in the progression of atherosclerosis. Nat Med 5 (1999) 1313-1316
23. Hollestelle S.C.G., de Vries M.R., van Keulen J.K., et al. Toll-like receptor 4 is involved in outward artery remodeling. Circulation 109 (2004) 393-398
24. Meir K.S., and Leitersdorf E. Atherosclerosis in the apolipoprotein E-deficient mouse-a decade of progress. Arterioscler Thromb Vasc Biol 24 (2004) 1006-1014
25. Rider B.J., Fraga E., Yu Q., and Singh B. Immune responses to self peptides naturally presented by murine class II major histocompatibility complex molecules. Mol Immunol 33 (1996) 625-633
26. Nelson C.A., Petzoid S.J., and Unanue E.R. Peptides determine the lifespan of MHC II molecules in the antigen-presenting cell. Nature 371 (1994) 250-252
27. Dai E., Guan H., Liu L., et al. Serp-1, a viral anti-inflammatory Serpin, regulates cellular serine proteinase and Serpin responses to vascular injury. J Biol Chem 278 (2003) 18563-18572
28. Proudfoot A.E.I., Handell T.M., Johnson Z., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci 100 (2003) 1885-1890
29. Wetterau J.R., Aggerbeck L.P., Rall S.C., and Weisgraber K.H. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem 263 (1988) 6240-6248
30. Aggerbeck L.P., Wetterau J.R., Weisgraber K.H., Wu C.S., and Lindgren F.T. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 263 (1988) 6249-6258
31. Dong L.M., Wilson C., Wardell M.R., et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 269 (1994) 22358-22365
32. Llodra J., Angeli V., Liu J., et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 101 (2004) 11779-11784
33. Summers K.L., Annette A.M., Stephens T.A., Mahon J.L., and Singh B. Dendritic cells and Immune regulation in the pathogenesis and prevention of Type 1 diabetes. Can J Diabetes 28 (2004) 20-29